Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 9/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304633 | 0.85 | DRD2 (0.44) | DRD2HTR4ACHECHRM4CHRM5 | |
| SCHEMBL7029357 | 0.81 | QDPR (0.52) | DRD2HTR1DMEN1KMT2A | |
| SCHEMBL7938441 | 0.78 | KDM4E (0.46) | — | |
| SCHEMBL6716473 | 0.77 | DRD2 (0.42) | DRD2HTR1DMEN1KMT2A | |
| SCHEMBL8304631 | 0.76 | HTR4 (0.36) | DRD2HTR4ACHEHTR1AMEN1 | |
| SCHEMBL6924205 | 0.76 | ABCB1 (0.43) | DRD2CHRM4CHRM5HTR1DADRA1B | |
| SCHEMBL7880812 | 0.76 | HTR2A (0.47) | HTR1AHTR1DHTR2BHTR3ADRD1 | |
| SCHEMBL6646479 | 0.75 | DRD2 (0.52) | DRD2HTR1AADRA1BMEN1KMT2A | |
| SCHEMBL6717514 | 0.75 | EHMT2 (0.42) | DRD2HTR1DMEN1KMT2A | |
| SCHEMBL328237 | 0.74 | HTR1D (0.49) | DRD2CHRM4CHRM5HTR1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038982-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| EP-1313477-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040038982-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| EP-1313477-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002005819-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038982-A1 | Compounds and methods | CCR5, CXCR3, CCR2 | DRD2 645/4885HTR4 616/4885ACHE 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.